Has Christopher Pearson received payments from drug or device companies?

Yes. Drug and device makers reported $10,878 in general payments to Christopher Pearson across 78 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Pearson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Pearson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Pearson

Optometrist · Longwood, FLNPI 1043312622

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (34.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 57.6% of the total. Reporting peaked in 2024 at $4,129 and has fallen 82.1% since, to $737 in 2025. Among optometrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,878in general payments, 2019–2025

Across 78 payments — averaging $139.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson Vision Care, Inc.$6K
Vertical Pharmaceuticals, LLC$2K
Alcon$1K
Bausch & Lomb Americas Inc.$438
Coopervision Inc.$407
Biotissue Holdings Inc.$145
plus $758 from 8 others

$2,488,618in research payments, 2019–2025

Across 1,347 payments — averaging $1847.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Johnson & Johnson Vision Care, Inc.$1.4M
Alcon Research LLC$793K
Oyster Point Pharma, Inc.$250K
Bausch & Lomb Americas Inc.$33K
Osmotica Pharmaceutical Corp.$12K

What the payments were for

Consulting fees$3,00028%
Speaking & faculty fees$2,20520%
Travel & lodging$1,88517%
Food & beverage$3,70734%
Entertainment$811%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson Vision Care, Inc.	29	$6,271
Vertical Pharmaceuticals, LLC	1	$1,500
Alcon	19	$1,358
Bausch & Lomb Americas Inc.	5	$438
Coopervision Inc.	10	$407
Biotissue Holdings Inc.	2	$145
Amgen	1	$122
Tarsus Pharmaceuticals, Inc.	1	$122
Rxsight Inc	1	$110
Bausch & Lomb, A Division Of Bausch Health US, LLC	4	$106
AbbVie	1	$94
Optovue, Inc.	1	$85
Optos, Inc.	1	$81
Novartis	2	$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,878 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida →

Medicare billing

Part B allowed, 2024

$12,280

Medicare patients

Services billed

145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Latanoprost	28	$239
Timolol Maleate	15	$112

Paid to pharmacies, not to this prescriber.

Other optometrist in Longwood

James HoffmanOrange Park$795K
April JasperWest Palm Beach$553K
Nora CothranLargo$505K
Michael SluskyNorth Port$384K
Katie SpearDefuniak Springs$361K
Karen HoffmanOrange Park$282K
Ashley RothMiami Beach$261K
Jessica SteenDavie$256K
Mark DunbarMiami$236K
Robert DavisPembroke Pines$217K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →